HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences gets USFDA’s final nod for Estradiol and Levonorgestrel Transdermal System
Oct-21-2026

Zydus Lifesciences has received United States Food and Drug Administration’s (USFDA) final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. (URLD: Climara Pro Transdermal System 0.045 mg/0.015 mg per day). 

The ANDA has been designated by the USFDA as a Competitive Generic Therapy (CGT). The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S. Federal Food, Drug, and Cosmetic Act. Any exclusivity period, where applicable, would commence upon first commercial marketing of the product.

Estradiol and Levonorgestrel Transdermal System is primarily used treat moderate to severe symptoms of menopause. It is also used in postmenopausal women for prevention of osteoporosis. The product will be manufactured at the group’s manufacturing plant at Moraiya, near Ahmedabad, Gujarat. Estradiol and Levonorgestrel Transdermal System had annual sales of around $45.7 million in the United States. The Group now has 458 approvals and has so far filed 516 (As on Sept 30, 2026) ANDA with the USFDA.

Zydus Lifesciences is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating, manufacturing, marketing and selling of finished dosage human formulations, active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products.

  RELATED NEWS >>